cnbc.com
“The beauty of our industry is that it’s very resilient and what we sell is mission critical,” said CEO Hardeep Gulati, in an interview with CNBC on Thursday.
11 months ago
cnbc.com
On Tuesday, several firms initiated coverage of Structure Therapies with buy and outperform ratings, driving up shares more than 6%.
11 months ago
cnbc.com
As Alzheimer’s patients seek treatment, they will need MRIs, blood tests and other diagnostics, fueling increased demand for these important tools.
6 months ago
cnbc.com
While Novo Nordisk’s Select study stoked confidence in the weight loss drug market, it spooked holders of medtech and liver disease stocks seen losing out.
6 months ago
cnbc.com
A number of early-stage drug delivery companies are flying under investors’ radar. Some can help patients avoid injections or IVs.
5 months ago
cnbc.com
The popularity of new diabetes and weight loss drugs have been bad news for diabetes device makers, but the news may not be all bad.
5 months ago
cnbc.com
A fit population would have different habits that could ripple through the economy and eventually be felt by the real estate industry, Jefferies predicts.
4 months ago
Search by beat, location, outlet & position to find the right journalists for your story.
Sign up for freecnbc.com
Evercore ISI initiated coverage of an immunology and inflammation drug developer at an outperform, saying the market is underpricing its odds for success.
4 months ago
cnbc.com
The eye-popping predictions for weight loss drug sales hinge on insurance coverage of the pricey treatments, and momentum seems to be building on that front.
3 months ago
cnbc.com
GLP-1 medications could have far-reaching implications for a wide variety of conditions, from liver disease to sleep apnea to heart disease.
3 months ago
cnbc.com
Companies — both big and small — are hoping to grab a piece of the lucrative anti-obesity drug market. Piper Sandler counts 78 agents in development.
3 months ago
